Compare Ishares Msci Thailand Etf (THD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs State Street SPDR S&P Biotech ETF — how do they compare? Ishares Msci Thailand Etf trades at $71.62 (market cap $426.83M), while State Street SPDR S&P Biotech ETF trades at $150.56 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 23.7× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is more actively traded (82,409 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Thailand Etf for 65 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| THD | XBI | |
|---|---|---|
Market Cap | $426.83M | $10.11B |
Volume | 82,409 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $75.06 | $169.55 |
52-Week Low | $57.86 | $104.99 |
Typical Hold Time | 65 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD trades at $71.80, down 0.15% with a bearish technical outlook as moving averages signal selling pressure. Short interest surged 90.6% in September 2026, indicating growing skepticism. The ETF has delivered strong 38% returns over the past year, outperforming ASEAN peers, but faces headwinds from potential profit-taking in AI-exposed holdings like Delta Electronics.
The outlook is cautious given elevated short interest and technical weakness. While THD benefits from Thailand's AI hardware exposure, concentration risk and regional capital outflows pose challenges. Investors should weigh strong historical performance against near-term sentiment pressures.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
